Lilly’s prasugrel could face new delay-WEB ONLY
A stock analyst says Eli Lilly and Co’s potential blockbuster drug prasugrel could face another Food and Drug Administration delay, Bloomberg News reported this morning. The experimental blood thinner may not receive U.S. action until the second quarter after regulators said they made a “mistake” removing a critic of the drug from an advisory panel […]